{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:56:10Z","timestamp":1753890970538,"version":"3.41.2"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011937","name":"Nieders\u00e4chsische Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011937","name":"Nieders\u00e4chsische Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Here, we described the case of a B cell-deficient patient after CD19 CAR-T cell therapy for refractory B cell Non-Hodgkin Lymphoma with protracted coronavirus disease 2019 (COVID-19). For weeks, this patient only inefficiently contained the virus while convalescent plasma transfusion correlated with virus clearance. Interestingly, following convalescent plasma therapy natural killer cells matured and virus-specific T cells expanded, presumably allowing virus clearance and recovery from the disease. Our findings, thus, suggest that convalescent plasma therapy can activate cellular immune responses to clear SARS-CoV-2 infections. If confirmed in larger clinical studies, these data could be of general importance for the treatment of COVID-19 patients.<\/jats:p>","DOI":"10.3389\/fimmu.2021.721738","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T07:45:00Z","timestamp":1628754300000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Berislav","family":"Bo\u0161njak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Odak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Graalmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Steinbr\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Blasczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine S.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Heinrich","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhold","family":"F\u00f6rster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: Current State of the Science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020008423","article-title":"Convalescent Plasma Therapy for B-Cell\u2013Depleted Patients With Protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.02.008","article-title":"The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-Analysis","volume":"96","author":"Klassen","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108662","article-title":"SARS-CoV-2 Infection Associated With Hepatitis in an Infant With X-Linked Severe Combined Immunodeficiency","volume":"224","author":"van Oers","year":"2021","journal-title":"Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"108723","DOI":"10.1016\/j.clim.2021.108723","article-title":"Treatment of B-Cell Depleted COVID-19 Patients With Convalescent Plasma and Plasma-Based Products","volume":"227","author":"Kenig","year":"2021","journal-title":"Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01064-3","article-title":"Convalescent Plasma in Patients Hospitalised With COVID-19","volume":"6736","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00573-9","article-title":"Low Serum Neutralizing Anti-SARS-CoV-2 S Antibody Levels in Mildly Affected COVID-19 Convalescent Patients Revealed by Two Different Detection Methods","volume":"18","author":"Bo\u0161njak","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4690-10-158","article-title":"CD56negCD16+ NK Cells Are Activated Mature NK Cells With Impaired Effector Function During HIV-1 Infection","volume":"10","author":"Milush","year":"2013","journal-title":"Retrovirology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent Plasma in Covid-19: Possible Mechanisms of Action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21037\/aob-2020-cp-01","article-title":"COVID-19 Convalescent Plasma: Mechanisms of Action and Rationale for Use: A Narrative Review","volume":"6","author":"Al-Riyami","year":"2021","journal-title":"Ann Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2031893","article-title":"Convalescent Plasma Antibody Levels and the Risk of Death From COVID-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing Monoclonal Antibodies for Treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0247640","article-title":"Presence of Antibody-Dependent Cellular Cytotoxicity (ADCC) Against SARS-CoV-2 in COVID-19 Plasma","volume":"16","author":"Tso","year":"2021","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0359-5","article-title":"Dissecting Antibody-Mediated Protection Against SARS-CoV-2","volume":"20","author":"Zohar","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.10.6829","article-title":"Antibodies and CD8 + T Cells Are Complementary and Essential for Natural Resistance to a Highly Lethal Cytopathic Virus","volume":"175","author":"Fang","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1003207","DOI":"10.1371\/journal.ppat.1003207","article-title":"Cooperativity Between CD8+ T Cells, non-Neutralizing Antibodies, and Alveolar Macrophages Is Important for Heterosubtypic Influenza Virus Immunity","volume":"9","author":"Laidlaw","year":"2013","journal-title":"PloS Pathog"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciab072","article-title":"Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study","volume":"2019","author":"Hensley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent Plasma in Patients Admitted to Hospital With COVID-19 (RECOVERY): A Randomised Controlled, Open-Label, Platform Trial","volume":"397","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.721738\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T07:45:03Z","timestamp":1628754303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.721738\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2021.721738"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.721738","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"article-number":"721738"}}